Polygenic hazard scores in age-associated Alzheimer’s disease
Last Updated on April 19, 2017 by Joseph Gut – thasso
Using genotype data from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer’s Project (IGAP Stage 1), the researchers identified AD-associated SNPs (at p <10−5). They then integrated these AD-associated SNPs into a Cox proportional hazard model using genotype data from a subset of 6,409 AD patients and 9,386 older controls from Phase 1 of the Alzheimer’s Disease Genetics Consortium (ADGC), providing a polygenic hazard score (PHS) for each participant. By combining population-based incidence rates and the genotype-derived PHS for each individual, they derived estimates of instantaneous risk for developing AD, based on genotype and age, and tested replication in multiple independent cohorts (ADGC Phase 2, National Institute on Aging Alzheimer’s Disease Center [NIA ADC], and Alzheimer’s Disease Neuroimaging Initiative [ADNI], total n = 20,680). Within the ADGC Phase 1 cohort, individuals in the highest PHS quartile developed AD at a considerably lower age and had the highest yearly AD incidence rate. Among APOE E3/3 individuals, the PHS modified expected age of AD onset by more than 10 years between the lowest and highest deciles (hazard ratio 3.34, 95% CI 2.62–4.24, p = 1.0 × 10−22). In independent cohorts, the PHS strongly predicted empirical age of AD onset (ADGC Phase 2, r = 0.90, p = 1.1 × 10−26) and longitudinal progression from normal aging to AD (NIA ADC, Cochran–Armitage trend test, p = 1.5 × 10−10), and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 × 10−6, and Consortium to Establish a Registry for Alzheimer’s Disease score for neuritic plaques, p = 6.8 × 10−6) and in vivo markers of AD neurodegeneration (ADNI, volume loss within the entorhinal cortex, p = 6.3 × 10−6, and hippocampus, p = 7.9 × 10−5).
Additional prospective validation of these results populations outside of the US, and possibly of different ethnic backgrounds along with prospective community-based cohorts are necessary in order to confirm a global applicability of these findings and make them validated for generalised clinical use in prospective disease risk examination and. possibly, prospective use of preventative therapeutic intervention in patients at high risk for the development of AD, particularly at early age.
Related articles across the web
Related posts
Children: Is there personalized medicine for children too?
April ...
April 4, 2017Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death
June 0...
June 8, 2019Genetic Study Strengthens Causal Role of BMI in Heart Disease
July 0...
July 7, 2017Hidden secrets in African genomes revealed by large scale sequencing
Octobe...
October 20, 2019Erenumab-Aooe (Aimovig): Novel preventive treatment for migraine approved
...
June 29, 2018